title: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
abstract: BACKGROUND
  Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
  
  
  METHODS
  PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma who have received between one and three previous treatment regimens. Patients were randomly assigned (1:1) via an interactive web-based and voice response system, stratified by number of previous treatment lines and by previous use of bortezomib, to receive 21 day cycles of placebo or panobinostat (20 mg; on days 1, 3, 5, 8, 10, 12, orally), both in combination with bortezomib (1·3 mg/m(2) on days 1, 4, 8, 11, intravenously) and dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, orally). Patients, physicians, and the investigators who did the data analysis were masked to treatment allocation; crossover was not permitted. The primary endpoint was progression-free survival (in accordance with modified European Group for Blood and Marrow Transplantation criteria and based on investigators' assessment) and was analysed by intention to treat. The study is ongoing, but no longer recruiting, and is registered at ClinicalTrials.gov, number NCT01023308.
  
  
  RESULTS
  768 patients were enrolled between Jan 21, 2010, and Feb 29, 2012, with 387 randomly assigned to panobinostat, bortezomib, and dexamethasone and 381 to placebo, bortezomib, and dexamethasone. Median follow-up was 6·47 months (IQR 1·81-13·47) in the panobinostat group and 5·59 months (2·14-11·30) in the placebo group. Median progression-free survival was significantly longer in the panobinostat group than in the placebo group (11·99 months [95% CI 10·33-12·94] vs 8·08 months [7·56-9·23]; hazard ratio [HR] 0·63, 95% CI 0·52-0·76; p<0·0001). Overall survival data are not yet mature, although at the time of this analysis, median overall survival was 33·64 months (95% CI 31·34-not estimable) for the panobinostat group and 30·39 months (26·87-not estimable) for the placebo group (HR 0·87, 95% CI 0·69-1·10; p=0·26). The proportion of patients achieving an overall response did not differ between treatment groups (235 [60·7%, 95% CI 55·7-65·6] for panobinostat vs 208 [54·6%, 49·4-59·7] for placebo; p=0·09); however, the proportion of patients with a complete or near complete response was significantly higher in the panobinostat group than in the placebo group (107 [27·6%, 95% CI 23·2-32·4] vs 60 [15·7%, 12·2-19·8]; p=0·00006). Minimal responses were noted in 23 (6%) patients in the panobinostat group and in 42 (11%) in the placebo group. Median duration of response (partial response or better) was 13·14 months (95% CI 11·76-14·92) in the panobinostat group and 10·87 months (9·23-11·76) in the placebo group, and median time to response (partial response or better) was 1·51 months (1·41-1·64) in the panobinostat group and 2·00 months (1·61-2·79) in the placebo group. Serious adverse events were reported in 228 (60%) of 381 patients in the panobinostat group and 157 (42%) of 377 patients in the placebo group. Common grade 3-4 laboratory abnormalities and adverse events (irrespective of association with study drug) included thrombocytopenia (256 [67%] in the panobinostat group vs 118 [31%] in the placebo group), lymphopenia (202 [53%] vs 150 [40%]), diarrhoea (97 [26%] vs 30 [8%]), asthenia or fatigue (91 [24%] vs 45 [12%]), and peripheral neuropathy (67 [18%] vs 55 [15%]).
  
  
  CONCLUSIONS
  Our results suggest that panobinostat could be a useful addition to the treatment armamentarium for patients with relapsed or relapsed and refractory multiple myeloma. Longer follow up will be necessary to determine whether there is any effect on overall survival.
  
  
  BACKGROUND
  Novartis Pharmaceuticals.
authors.affiliation: Clínica Universidad de Navarra-CIMA, Pamplona, Spain. Electronic address: sanmiguel@unav.es.
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San-Miguel
authors.affiliation: Santa Casa de Misericordia de São Paulo Hospital, São Paulo, Brazil.
authors.forename: Vânia T M
authors.initials: VT
authors.lastname: Hungria
authors.affiliation: Seoul National University Hospital, Seoul, South Korea.
authors.forename: Sung-Soo
authors.initials: SS
authors.lastname: Yoon
authors.affiliation: Ankara University School of Medicine, Ankara, Turkey.
authors.forename: Meral
authors.initials: M
authors.lastname: Beksac
authors.affiliation: University of Athens School of Medicine, Athens, Greece.
authors.forename: Meletios Athanasios
authors.initials: MA
authors.lastname: Dimopoulos
authors.affiliation: Alexandria University, Alexandria, Egypt.
authors.forename: Ashraf
authors.initials: A
authors.lastname: Elghandour
authors.affiliation: Medical University of Warsaw, Warsaw, Poland.
authors.forename: Wieslaw Wiktor
authors.initials: WW
authors.lastname: Jedrzejczak
authors.affiliation: University of Kiel, Kiel, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Günther
authors.affiliation: Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
authors.forename: Thanyaphong Na
authors.initials: TN
authors.lastname: Nakorn
authors.affiliation: Siriraj Hospital, Bangkok, Thailand.
authors.forename: Noppadol
authors.initials: N
authors.lastname: Siritanaratkul
authors.affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
authors.affiliation: Ramathibodi Hospital, Bangkok, Thailand.
authors.forename: Suporn
authors.initials: S
authors.lastname: Chuncharunee
authors.affiliation: Chonnam National University Hwasun Hospital, Hwasun, South Korea.
authors.forename: Je-Jung
authors.initials: JJ
authors.lastname: Lee
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Robert L
authors.initials: RL
authors.lastname: Schlossman
authors.affiliation: Clinic of Professional Pathology and Haematology, Saratov State Medical University, Saratov, Russia.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Shelekhova
authors.affiliation: UCL Cancer Institute, University College London, London, UK.
authors.forename: Kwee
authors.initials: K
authors.lastname: Yong
authors.affiliation: Singapore General Hospital, Singapore.
authors.forename: Daryl
authors.initials: D
authors.lastname: Tan
authors.affiliation: Phramongkutklao Hospital, Bangkok, Thailand.
authors.forename: Tontanai
authors.initials: T
authors.lastname: Numbenjapon
authors.affiliation: St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
authors.forename: Jamie D
authors.initials: JD
authors.lastname: Cavenagh
authors.affiliation: Chang Zheng Hospital, Shanghai, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
authors.affiliation: Maisonneuve-Rosemont Hospital and University of Montreal, Montreal, QC, Canada.
authors.forename: Richard
authors.initials: R
authors.lastname: LeBlanc
authors.affiliation: Karolinska University Hospital, Stockholm, Sweden.
authors.forename: Hareth
authors.initials: H
authors.lastname: Nahi
authors.affiliation: State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
authors.forename: Lugui
authors.initials: L
authors.lastname: Qiu
authors.affiliation: Asklepios Clinic Altona, Hamburg, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Salwender
authors.affiliation: Spirito Santo Hospital, Pescara, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Pulini
authors.affiliation: Nantes University Hospital, Nantes, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Institute of Haematology and Transfusion Medicine, Warsaw, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
authors.affiliation: Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada.
authors.forename: Darrell
authors.initials: D
authors.lastname: White
authors.affiliation: Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Bladé
authors.affiliation: Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
authors.forename: WenMing
authors.initials: W
authors.lastname: Chen
authors.affiliation: University Hospital La Fe and Universidad Católica San Vicente Mártir, Valencia, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: de la Rubia
authors.affiliation: Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
authors.forename: Peter
authors.initials: P
authors.lastname: Gimsing
authors.affiliation: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
authors.forename: Sagar
authors.initials: S
authors.lastname: Lonial
authors.affiliation: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Kaufman
authors.affiliation: University Hospital and Cancer Research Center, University of Salamanca-Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Salamanca, Spain.
authors.forename: Enrique M
authors.initials: EM
authors.lastname: Ocio
authors.affiliation: Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: Ljupco
authors.initials: L
authors.lastname: Veskovski
authors.affiliation: Kyungpook National University, Daegu, South Korea.
authors.forename: Sang Kyun
authors.initials: SK
authors.lastname: Sohn
authors.affiliation: Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
authors.forename: Ming-Chung
authors.initials: MC
authors.lastname: Wang
authors.affiliation: Gachon University Gil Medical Center, Incheon, South Korea.
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.affiliation: University Hospital Würzburg, Würzburg, Germany.
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Monika
authors.initials: M
authors.lastname: Sopala
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Claudia
authors.initials: C
authors.lastname: Corrado
authors.affiliation: Novartis Pharma AG, Basel, Switzerland.
authors.forename: Bourras-Rezki
authors.initials: BR
authors.lastname: Bengoudifa
authors.affiliation: Novartis Pharma SAS, Rueil-Malmaison, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Binlich
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: Paul G
authors.initials: PG
authors.lastname: Richardson
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D000077767:Panobinostat; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D006877:Hydroxamic Acids; D007211:Indoles; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D000077767:Panobinostat